About Us
Who We Are
We are an international specialist healthcare company, developing and commercialising products targeting critical care, cancer and other disorders.
Our mission is to bring to market medical products that meet the needs of specialist physicians and their patients, and in doing so to build a sustainable, profitable business that delivers superior returns to our shareholders.
Through our US commerical operations, we market and sell CroFab® (crotalidae polyvalent immune fab (ovine)), our Crotalid snake bite antivenom, DigiFab® (digoxin immune fab (ovine)), our antidote for digoxin overdose and most recently Voraxaze® (glucarpidase), for the treatment of methotrexate toxicity.
In early 2011, we completed the acquisition of Biocompatibles International plc. This has expanded our commercial business with the addition of approved interventional oncology products, and has broadened our pipeline of internal development programmes.
We’re looking to grow our business and are seeking to acquire new products to develop and market to specialist healthcare physicians in the US.
BTG at a glance
Our latest Corporate Profile provides a snapshot of us today.
Corporate Profile
Download document (PDF - 110KB)
Developing innovative new products
We have an internal development pipeline of innovative products, some of which we plan to take to market ourselves, others which we intend to partner at key stages in their development.
Our culture
Find out about how we’re building a collaborative spirit, based on mutual respect, where employees have a clear sense of purpose.